Lee's Pharmaceutical Holdings (HKSE:00950) GF Score : 79/100 (As of Dec. 11, 2024)

View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings GF Score?

Lee's Pharmaceutical Holdings has the GF Score of 79, which implies that the company is Likely to have average performance.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 7/10
3. Growth Rank : 5/10
4. GF Value Rank : 9/10
5. Momentum Rank : 7/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Lee's Pharmaceutical Holdings is Likely to have average performance.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Lee's Pharmaceutical Holdings's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lee's Pharmaceutical Holdings's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's GF Score falls into.

Lee's Pharmaceutical Holdings (HKSE:00950) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Lee's Pharmaceutical Holdings GF Score Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Lee's Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » GF Score

Traded in Other Exchanges

LPCUF:USA L1PA:Germany

Address

Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG

Website

https://www.leespharm.com

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Executives

Leelalertsuphakun Wanee	2101 Beneficial owner
Huang Zuie-chin	2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky	2202 Interest of your spouse
Li Xiaoyi	2101 Beneficial owner
Lee Siu Fong	2101 Beneficial owner
Ubs Group Ag	2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p.	2101 Beneficial owner
Panacea Innovation Limited	2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Qualister Sa	2101 Beneficial owner
Paponi Claudia	2202 Interest of your spouse
Cavazza Paolo	2201 Interest of corporation controlled by you
Apta Finance Sa	2201 Interest of corporation controlled by you
Fmr Llc	2201 Interest of corporation controlled by you
Gsr Capital Joy Corporation	2101 Beneficial owner

Lee's Pharmaceutical Holdings Headlines

No Headlines